Frontiers in Microbiology · مجلد 17 · 1881796-1881796
Helicobacter pylori is one of the most prevalent pathogenic microorganisms worldwide. The treatment of H. pylori infections is challenging due to the increasing antibiotic resistance. Therefore, alternative therapies are crucial for addressing these issues. This study aimed to investigate alternative approaches to combat H. pylori infection using lactic acid bacteria. Nineteen LAB isolates exhibited strong tolerance to simulated gastric acid and bile salts, as well as notable auto-aggregation and co-aggregation capabilities. Among them, isolates L20, L22, and L40 showed superior performance. Their neutralized cell-free supernatants (n-CFSs) significantly inhibited H. pylori urease production by 69, 66, and 67%, respectively, and reduced biofilm formation by 88, 82, and 80%, respectively. Molecular identification revealed that isolates L20 and L40 belonged to Lactiplantibacillus plantarum , while L22 was identified as Limosilactobacillus fermentum . Furthermore, the n-CFS of L. plantarum L20 markedly downregulated the expression of H. pylori virulence genes, including vacA , cagA , ureA , and babA, with fold reductions of 79, 68, 90, and 96%, respectively. In vivo , treatment with L. plantarum L20 n-CFS resulted in 1.28 log reduction in H. pylori colonization ( p < 0.001). Proteomic analysis further identified metabolically active proteins associated with catalytic and secondary metabolite pathways, supporting their mechanistic role in anti- H. pylori activity. These findings highlight the potential of LAB-derived n-CFS, particularly L. plantarum L20, as a promising antivirulent strategy against H. pylori infections.
Frontiers in Microbiology · مجلد 16 · 1707017-1707017
Aim Klebsiella pneumoniae ( K. pneumoniae ) is an opportunistic pathogen causing infections ranging from pulmonary disease to severe systemic illness. This study aimed to examine the relationships between infection site, pathotype, virulence, resistance, and clinical presentations to manage classical (cKp) and hypervirulent (hvKp) strains. Methods and results 600 clinical specimens were screened for K. pneumoniae . Virulence and resistance fitness were analyzed phenotypically and genotypically. Clinical correlations were assessed to link pathotype, resistance, virulence, infection site, age, and presentation. K. pneumoniae was detected in 17.2% specimens (103/600), with pulmonary samples showing 43% positivity versus 12% in extra-pulmonary ones. hvKp accounted for 55.3% and cKp for 44.7% of isolates; hvKp predominated in extra-pulmonary infections (83.3%) and cKp in pulmonary cases (83.7%). K1 (33.1%) and K2 (21.4%) were confined to hvKp, while pulmonary isolates were mainly K3, K5, and K20. Pulmonary infections mainly affected adults (81.4%) and showed respiratory signs; extra-pulmonary cases occurred mostly in pediatric (46.7%) and elderly (41.7%) patients with systemic symptoms such as fever and hypotension. Clustering distinguished pulmonary/cKp (MDR-rich) from extra-pulmonary/hvKp (virulence-rich) isolates, with some overlap indicating hybrid strains. Correlations linked pulmonary infections with cKp and MDR (r = 0.67), and extra-pulmonary infections with hvKp and systemic disease (r = 0.67). Conclusion The high MDR burden of cKp underscores the need for stronger antimicrobial stewardship and new therapies, while the invasive nature of hvKp highlights the importance of early recognition and rapid intervention to prevent systemic complications. Early distinction of cKp from hvKp can significantly influence treatment decisions and reduce morbidity and mortality associated with K. pneumoniae infections.
Abstract Enterobacter cloacae is infrequently reported in milk samples and bovine mastitis. Here we report for the first time, the detection and phylogenomic analysis of an Enterobacter cloacae strain isolated from a raw milk sample obtained from a clinical mastitis-infected cow in Bangladesh using whole genome sequence analyses. Enterobacter cloacae strain BRMHR107Ecl belonged to sequence type ST84, belonging to a rarely reported ST in the Enterobacter genus. Phylogenomic analyses revealed that the strain is closely related to a strain previously isolated in Bangladesh. The closest relative to BR-MHR107Ecl was a strain isolated in 2016 from a human rectal swab sample in Nigeria. The BR-MHR107Ecl strain co-harbored beta-lactamase genes including bla DHA-1 and bla CMH-3-like . Other antimicrobial resistance genes were detected and included aminoglycoside resistance genes ( aph(3″)-Ib-like, aph(6)-Id ), fluoroquinolone resistance gene ( qnr B4) and sulphonamide resistance gene ( sul 1). The genome harbored an additional disinfectant resistance gene ( qacE -like). Several plasmid replicons, including Col(pHAD28), IncFIA(HI1), IncFIB(K), IncR, and repB(R1701) were detected. Virulence genes encoding for heat-stable enterotoxin EAST-1 ( astA ) and lipoprotein NlpI precursor ( nlpI ) were detected. The multidrug resistance and virulence genes repertoire of BR-MHR107Ecl and its isolation from bovine mastitis milk render it a potentially significant public health concern, highlighting its emerging threat to dairy herds and underscoring the importance of genomic surveillance in food animals and non-clinical environment to detect emerging pathogens. This study will contribute to understanding the transmission of E. cloacae from farm-to-fork which requires collaborative and comprehensive One health approaches. The findings will help monitor the global dissemination of antimicrobial resistance in livestock-associated Enterobacter cloacae in the One Health context.
Frontiers in Cellular and Infection Microbiology · مجلد 16 · 1792519-1792519
Background Pseudomonas aeruginosa ( P. aeruginosa ) causes healthcare- and community-associated infections with high antimicrobial resistance and virulence diversity. The type III secretion system (T3SS) effectors genotypes ( exoS+, exoU+, exoT+, and exoY+ ) play central roles in pathogenesis, yet their relationships with antimicrobial resistance, virulence profiles, serotypes, and clinical manifestations remain incompletely defined. Methods Five hundred clinical specimens, sputum, urine, burn, wound, and eye exudates, 100 each, were collected from multiple hospitals for isolation of P. aeruginosa. Phenotypic and genotypic methods identified isolates and characterized T3SS effector genotypes, antimicrobial susceptibility, resistance genes, virulence genes, and serotypes. Clustering, strain typing, and correlation analyses assessed associations among resistance, virulence, epidemiology, and disease severity. Results Among 125 isolates, exoS+ was the most prevalent T3SS effector, followed by exoU+, while exoT+ and exoY+ were less frequent. The exoU+ isolates were consistently associated with severe clinical manifestations across specimen types and were more often hospital acquired, with enrichment for serotypes O6 and O11. The exoS+ isolates showed broader serotype diversity with balanced hospital and community acquisition, whereas ExoT and ExoY were mainly associated with O6 and O11, with ExoY more common in community-acquired cases but less prevalent overall. Despite widespread antimicrobial resistance and broad distribution of resistance genes, polymyxin remained the most effective agent, with a low resistance rate of 15.2%. Multidrug resistance affected 81.6% of isolates and was observed across all T3SS effector genotypes, with frequent coexistence of resistance and virulence genes within individual isolates. Hierarchical clustering revealed marked intra-group and inter-group heterogeneity, with no evidence of dominant clonal expansion by effector genotype or specimen type, and correlation analysis showed weak associations among resistance, virulence, serotypes, and epidemiological features, except for a consistent link between exoU+ and markers of severe tissue injury. Conclusions P. aeruginosa isolates form a heterogeneous, non-clonal population with independent resistance and virulence traits, while T3SS effector genotypes, especially exoU+, best predicts disease severity. The data suggest that pathogenicity in P. aeruginosa is driven by independently assorting resistance and virulence traits, not by fixed clonal backgrounds. These findings support integrating T3SS effector profiling into clinical risk assessment and surveillance.
Pseudomonas aeruginosatype III secretion systemexoSexoU
AIMS: Escherichia coli is a key pathogen causing gastrointestinal and urinary tract infections. Diarrheagenic E. coli (DEC) and uropathogenic E. coli (UPEC) are distinct major pathotypes linked to specific clinical outcomes. Therefore, this study aimed to compare DEC and UPEC isolates regarding distribution, antimicrobial resistance, serotypes, resistance, and virulence gene profiles. MATERIALS AND METHODS: A total of 400 clinical samples (200 stools and 200 urine) were analyzed using phenotypic and genotypic methods. Antimicrobial resistance, serotyping, and detection of resistance and virulence genes were performed. Phylogenetic and correlation analyses were conducted to explore genetic relationships and interactions. RESULTS: Of 97 E. coli isolates (24.25% prevalence), 56 DEC and 41 UPEC were detected. DEC isolates primarily included serotypes O26, O45, and O55, while UPEC predominantly featured O1 and O25. UPEC showed higher multidrug resistance, while DEC was more virulent. UPEC carried unique markers (ureC, papC), and DEC harbored stx and aggR genes associated with gastrointestinal infections. Phylogenetic analysis showed separate clustering for DEC and UPEC, with limited genetic overlap. Correlation analysis identified strong associations within resistance and virulence genes but a negative correlation between these traits. CONCLUSION: This study compared the phenotypic and genetic features of DEC and UPEC, highlighting their distinct pathogenic traits. Limited genetic overlap suggests potential gene transfer, influencing adaptability, and evolution.
This study aimed to investigate the potential of patuletin, a rare natural flavonoid, as a virulence and LasR inhibitor against Pseudomonas aeruginosa. Various computational studies were utilized to explore the binding of Patuletin and LasR at a molecular level. Molecular docking revealed that Patuletin strongly interacted with the active pocket of LasR, with a high binding affinity value of −20.96 kcal/mol. Further molecular dynamics simulations, molecular mechanics generalized Born surface area (MM/GBSA), protein-ligand interaction profile (PLIP), and essential dynamics analyses confirmed the stability of the patuletin-LasR complex, and no significant structural changes were observed in the LasR protein upon binding. Key amino acids involved in binding were identified, along with a free energy value of −26.9 kcal/mol. In vitro assays were performed to assess patuletin’s effects on P. aeruginosa. At a sub-inhibitory concentration (1/4 MIC), patuletin significantly reduced biofilm formation by 48% and 42%, decreased pyocyanin production by 24% and 14%, and decreased proteolytic activities by 42% and 20% in P. aeruginosa isolate ATCC 27853 (PA27853) and P. aeruginosa clinical isolate (PA1), respectively. In summary, this study demonstrated that patuletin effectively inhibited LasR activity in silico and attenuated virulence factors in vitro, including biofilm formation, pyocyanin production, and proteolytic activity. These findings suggest that patuletin holds promise as a potential therapeutic agent in combination with antibiotics to combat antibiotic-tolerant P. aeruginosa infections.
Frontiers in Cellular and Infection Microbiology · مجلد 13 · 1322778-1322778
The advent of nanotechnology has been instrumental in the development of new drugs with novel targets. Recently, metallic nanoparticles have emerged as potential candidates to combat the threat of drug-resistant infections. Diabetic foot ulcers (DFUs) are one of the dreadful complications of diabetes mellitus due to the colonization of numerous drug-resistant pathogenic microbes leading to biofilm formation. Biofilms are difficult to treat due to limited penetration and non-specificity of drugs. Therefore, in the current investigation, SnO2 nanoparticles were biosynthesized using Artemisia vulgaris (AvTO-NPs) as a stabilizing agent and were characterized using ultraviolet–visible (UV–vis) spectroscopy, Fourier transform infrared spectroscopy (FT-IR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy-dispersive X-ray spectroscopy (EDX). Furthermore, the efficacy of AvTO-NPs against biofilms and virulence factors of drug-resistant Candida albicans strains isolated from DFUs was assessed. AvTO-NPs displayed minimum inhibitory concentrations (MICs) ranging from 1 mg/mL to 2 mg/mL against four strains of C. albicans. AvTO-NPs significantly inhibited biofilm formation by 54.8%–87%, germ tube formation by 72%–90%, cell surface hydrophobicity by 68.2%–82.8%, and exopolysaccharide (EPS) production by 69%–86.3% in the test strains at respective 1/2xMIC. Biosynthesized NPs were effective in disrupting established mature biofilms of test strains significantly. Elevated levels of reactive oxygen species (ROS) generation in the AvTO-NPs-treated C. albicans could be the possible cause of cell death leading to biofilm inhibition. The useful insights of the present study could be exploited in the current line of treatment to mitigate the threat of biofilm-related persistent DFUs and expedite wound healing.
Staphylococcus aureus is a highly prevalent and aggressive human pathogen causing a wide range of infections. This study aimed to explore the potential of Patuletin, a rare natural flavone, as an anti-virulence agent against S . aureus . At a sub-inhibitory concentration (1/4 MIC), Patuletin notably reduced biofilm formation by 27 % and 23 %, and decreased staphyloxanthin production by 53 % and 46 % in Staphylococcus aureus isolate SA25923 and clinical isolate SA1, respectively. In order to gain a more comprehensive understanding of the in vitro findings, several in silico analyses were conducted. Initially, a 3D-flexible alignment study demonstrated a favorable structural similarity between Patuletin and B70 , the co-crystallized ligand of CrtM, an enzyme that plays a pivotal role in the biosynthesis of staphyloxanthin. Molecular docking highlighted the strong binding of Patuletin to the active site of CrtM, with a high affinity of −20.95 kcal/mol. Subsequent 200 ns molecular dynamics simulations, along with MM-GBSA, ProLIF, PLIP, and PCAT analyses, affirmed the stability of the Patuletin-CrtM complex, revealing no significant changes in CrtM's structure upon binding. Key amino acids crucial for binding were also identified. Collectively, this study showcased the effective inhibition of CrtM activity by Patuletin in silico and its attenuation of key virulence factors in vitro , including biofilm formation and staphyloxanthin production. These findings hint at Patuletin's potential as a valuable therapeutic agent, especially in combination with antibiotics, to counter antibiotic-resistant Staphylococcus aureus infections.
Frontiers in Cellular and Infection Microbiology · مجلد 14 · 1403219-1403219
Introduction Despite years of efforts to develop new antibiotics for eradicating multidrug-resistant (MDR) and multi-virulent Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Staphylococcus aureus (VRSA) infections, treatment failures and poor prognoses in most cases have been common. Therefore, there is an urgent need for new therapeutic approaches targeting virulence arrays. Our aim is to discover new anti-virulence therapies targeting MRSA and VRSA virulence arrays. Methodology We employed phenotypic, molecular docking, and genetic studies to screen for anti-virulence activities among selected promising compounds: Coumarin, Simvastatin, and Ibuprofen. Results We found that nearly all detected MRSA and VRSA strains exhibited MDR and multi-virulent profiles. The molecular docking results aligned with the phenotypic and genetic assessments of virulence production. Biofilm and hemolysin productions were inhibited, and all virulence genes were downregulated upon treatment with sub-minimum inhibitory concentration (sub-MIC) of these promising compounds. Ibuprofen was the most active compound, exhibiting the highest inhibition and downregulation of virulence gene products. Moreover, in vivo and histopathological studies confirmed these results. Interestingly, we observed a significant decrease in wound area and improvements in re-epithelialization and tissue organization in the Ibuprofen and antimicrobial treated group compared with the group treated with antimicrobial alone. These findings support the idea that a combination of Ibuprofen and antimicrobial drugs may offer a promising new therapy for MRSA and VRSA infections. Conclusion We hope that our findings can be implemented in clinical practice to assist physicians in making the most suitable treatment decisions.
Frontiers in Chemistry · مجلد 12 · 1286675-1286675
Chromobacterium violaceum an opportunistic human pathogenic bacterium, exhibits resistance to conventional antibiotics by exploiting its quorum sensing mechanism to regulate virulence factor expression. In light of this, disrupting the quorum sensing mechanism presents a promising avenue for treating infections caused by this pathogen. The study focused on using the cytoplasmic quorum sensing receptor CviR from C. violaceum as a model target to identify novel quorum sensing inhibitors from P. quassioides through in silico computational approaches. Molecular docking analyses unveiled that several phytochemicals derived from Picrasma quassioides exhibit the potential to inhibit quorum sensing by binding to CviR protein. Notably, the compounds such as Quassidine I (– 8.8 kcal/mol), Quassidine J (– 8.8 kcal/mol), Kumudine B (– 9.1 kcal/mol) and Picrasamide A (– 8.9 kcal/mol) exhibited high docking scores, indicating strong binding affinity to the CviR protein. The native ligand C6-HSL (N-hexanoyl-L-homoserine lactone) as a positive control/co-crystal inhibitor also demonstrated a significant binding energy of—7.7 kcal/mol. The molecular dynamics simulation for 200 ns showed the thermodynamic stability and binding affinity refinement of the top-ranked CviR inhibitor (Kumudine B) with its stable binding and minor fluctuations compared to positive control (C6-HSL). Pharmacokinetic predictions indicated that Kumudine B possesses favourable drug-like properties, which suggest its potential as a drug candidate. The study highlight Kumudine B as a potential agent for inhibiting the CviR protein in C. violaceum. The comprehensive evaluation of Kumudine B provides valuable insights into its pharmacological profiles, facilitating its assessment for diverse therapeutic applications and guiding future research activities, particularly as antibacterial agents for clinical drug development.
BACKGROUND: Antimicrobial-resistant Helicobacter pylori (H. pylori) poses a significant public health concern, especially given the limited therapeutic options for azithromycin-resistant strains. Hence, there is a necessity for new studies to reconsider the use of azithromycin, which has diminished in effectiveness against numerous strains. Thus, we aimed to augment azithromycin's anti-Helicobacter properties by combining it with curcumin in different formulations, including curcumin in clove oil, curcumin nano-gold emulsion, and curcumin nanoemulsion. METHODS: The antimicrobial activities of the investigated compounds, both individually and in combination with other anti-Helicobacter drugs, were evaluated. Their antibiofilm and anti-virulence properties were assessed using both phenotypic and genotypic methods, alongside molecular docking studies. Our findings were further validated through mouse protection assays and histopathological analysis. RESULTS: We observed high anti-Helicobacter activities of curcumin, especially curcumin nanoemulsion. A synergistic effect was detected between curcumin nanoemulsion and azithromycin with fraction inhibitory concentration index (FICI) values <0.5. The curcumin nanoemulsion was the most active anti-biofilm and anti-virulence compound among the examined substances. The biofilm-correlated virulence genes (babA and hopQ) and ureA genes were downregulated (fold change <1) post-treatment with curcumin nanoemulsion. On the protein level, the anti-virulence activities of curcumin nanoemulsion were documented based on molecular docking studies. These findings aligned with histopathological scoring of challenge mice, affirming the superior efficacy of curcumin nanoemulsion/azithromycin combination. CONCLUSION: The anti-Helicobacter activities of all curcumin physical forms pose significant challenges due to their higher minimum inhibitory concentration (MIC) values exceeding the maximum permissible level. However, using curcumin nanoemulsion at sub-MIC levels could enhance the anti-Helicobacter activity of azithromycin and exhibit anti-virulence properties, thereby improving patient outcomes and addressing resistant pathogens. Therefore, more extensive studies are necessary to assess the safety of incorporating curcumin nanoemulsion into H. pylori treatment.
BACKGROUND: Methicillin-Resistant Staphylococcus aureus (MRSA) is a global concern owing to the increasing prevalence of multidrug-resistant (MDR) strains. Vancomycin has been the primary treatment for MRSA; however, Vancomycin-resistant strains are being increasingly reported worldwide. Therefore, comparative studies are essential to support antimicrobial stewardship and improving clinical management. Ultimately, the findings from this study are expected to inform treatment strategies and guide public health interventions effectively. MATERIAL AND METHODS: This study investigated the prevalence, antimicrobial resistance, and virulence characteristics of Vancomycin-sensitive S. aureus (VSSA) and Vancomycin-resistant S. aureus (VRSA) within MRSA strains. By employing a combination of phenotypic methods, such as antimicrobial susceptibility testing, and genotypic techniques, including molecular typing and identification of virulence genes, we obtained comprehensive insights into VRSA and VSSA profiles. RESULTS: Of 250 clinical samples, 62 (24.8%) were S. aureus and 27 (43.5%) were identified as MRSA. All MRSA isolates exhibited MDR patterns. Most MRSA strains were VSSA (20/27, 74.1%), while 7 (25.9%) were VRSA. The VRSA isolates showed more antimicrobial resistance than VSSA isolates; however, the VRSA isolates had less virulence than VSSA isolates. Linezolid was the most effective treatment, with a 3.7% resistance rate. A higher percentage of biofilm-producing MRSA (96.3%) was confirmed by both phenotypic and genotypic methods. All isolates, except one VRSA, showed multi-virulence patterns (harbored more than 3 virulence genes). High diversity and low clonality (D-value = 0.99) were found in both VSSA and VRSA. Based on our correlation findings, the emergence of vancomycin resistance could modify the association between antimicrobial resistance and virulence, potentially affecting the pathogenic profile of these strains. The study also revealed complex interactions among host factors (including age and gender), sample origin, antimicrobial resistance, biofilm production, and virulence genes. CONCLUSION: This study highlights the alarming spread of MRSA and VRSA, which show significant resistance and virulence.
Frontiers in Cellular and Infection Microbiology · مجلد 13 · 1265027-1265027
Introduction: There is an urgent need to develop therapeutic options for biofilm-producing Staphylococcus aureus (S. aureus). Therefore, the renewed interest in essential oils (EOs), especially carvacrol, linalool and eugenol, has attracted the attention of our research group. Methods: Multidrug resistance and multivirulence profiles in addition to biofilm production of S. aureus strains isolated from cows with mastitis were evaluated using both phenotypic and genotypic methods. The antimicrobial and antibiofilm activities of EOs were tested using both in vitro and molecular docking studies. Moreover, the interactions between commonly used antibiotics and the tested EOs were detected using the checkerboard method. Results: We found that all our isolates (n= 37) were biofilm methicillin resistant S. aureus (MRSA) producers and 40.5% were vancomycin resistant S. aureus (VRSA). Unfortunately, 73 and 43.2% of the recovered MRSA isolates showed multidrug resistant (MDR) and multivirulence patterns, respectively. The antimicrobial activities of the tested EOs matched with the phenotypic evaluation of the antibiofilm activities and molecular docking studies. Linalool showed the highest antimicrobial and antibiofilm activities, followed by carvacrol and eugenol EOs. Fortunately, synergistic interactions between the investigated EOs and methicillin or vancomycin were detected with fractional inhibitory concentration index (FICI) values ≤ 0.5. Moreover, the antimicrobial resistance patterns of 13 isolates changed to sensitive phenotypes after treatment with any of the investigated EOs. Treatment failure of bovine mastitis with resistant S. aureus can be avoided by combining the investigated EOs with available antimicrobial drugs. Conclusion: We hope that our findings can be translated into a formulation of new pharmaceutical dosage forms against biofilm-producing S. aureus pathogens.
The worldwide crises from multi-drug-resistant (MDR) bacterial infections are pushing us to search for new alternative therapies. The renewed interest in medicinal plants has gained the attention of our research group. Tamarindus indica L. (T. indica) is one of the traditional medicines used for a wide range of diseases. Therefore, we evaluated the antimicrobial activities of ethanolic extract of T. indica. The inhibitions zones, minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and fractional inhibitor concentration indices (FICI) against Gram+ve and −ve pathogens were detected. The bioactive compounds from T. indica extract were identified by mass spectroscopy, thin-layer chromatography, and bio-autographic assay. We performed scanning electron microscopy (SEM) and molecular docking studies to confirm possible mechanisms of actions and antivirulence activities, respectively. We found more promising antimicrobial activities against MDR pathogens with MIC and MBC values for Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa), i.e., (0.78, 3.12 mg/mL) and (1.56, 3.12 mg/mL), respectively. The antimicrobial activities of this extract were attributed to its capability to impair cell membrane permeability, inducing bacterial cell lysis, which was confirmed by the morphological changes observed under SEM. The synergistic interactions between this extract and commonly used antibiotics were confirmed (FICI values < 0.5). The bioactive compounds of this extract were bis (2-ethylhexyl)phthalate, phenol, 2,4-bis(1,1-dimethylethyl), 1,2-benzenedicarboxylic acid, and bis(8-methylnonyl) ester. Additionally, this extract showed antivirulence activities, especially against the S. aureus protease and P. aeruginosa elastase. In conclusion, we hope that pharmaceutical companies can utilize our findings to produce a new formulation of T. indica ethanolic extract with other antibiotics.
The drug repurposing strategy is an alternative approach to reducing drug development timelines with low cost, especially during outbreaks of disease caused by drug-resistant pathogens. Rafoxanide can disrupt the abilities of bacterial and fungal cells to adapt to stress conditions. The coadministration of antibiotics with rafoxanide can prevent the failure of treatment of both resistant bacteria and fungi, as the resistant pathogens could be made sensitive upon treatment with rafoxanide. From our findings, we anticipate that pharmaceutical companies will be able to utilize new combinations against resistant pathogens.